In the News: New Treatment for Babies with Neonatal Abstinence Syndrome May Cut Hospital Stay

The Philadelphia Inquirer’s Marie McCullough reported on a recent study conducted by researchers at Thomas Jefferson University, which was published in The New England Journal of Medicine.

The study suggests treating babies who have neonatal abstinence syndrome (NAS) with buprenorphine could cut treatment time nearly in half, from an average of 28 days to 15 days.

Walter K. Kraft, M.D., first author of the Jefferson study, told McCullough, “This is a practice-changing advance for treatment of babies with NAS. We predict that buprenorphine will become the new standard of care.” Kraft added that in addition to its shortening treatment time, “Buprenorphine may have a built-in safety effect. Giving more of the drug won’t lead to a corresponding increase in toxicity.”

Two doctors in NICU

Drs. Walter Kraft and Susan Adeniyi-Jones

The Wall Street Journal, Science Magazine, Reuters and additional news media reported on the study.

, , ,

No comments yet.

Add Your Comments and Join the Conversation

Comments are moderated and generally will be posted if they are on-topic and not abusive.
View our commenting policy.